RLF/RLFTF a Swiss Phramaceutical firm that is traded on the SIX exchange under the ticker RLF and also on the OTCQB under the ticker RLFTF. Relief was one of the first companies that discussed an inhaled treatment for Covid-19. Zyesami, a formulation of Aviptadil, is an IV delivered treatment that has shown promising results for critically ill patients. In many regions that have available hospital capacity, and with frontline doctors desperate to help their patients; Zyesami could be a great boost to individuals with severe disease progression. Aviptadil, is similar to a polypeptide that is naturally occurring in the human body, and Aviptadil is a synthetic version of the polypeptide. Recently Aviptadil was reformulated to have a longer shelf life. There trials for Zyesami have been conducted by an American firm NeuroRx. An ongoing dispute over payments for trial expenses to be borne by Relief has lead to some statements by NeuroRx about the possibility of needing to renegotiate profit sharing. NeuroRx is traded in the US under the ticker symbol NRXP. See the most recent video, “RLFTF – BRPA Merger with NeuroRx plus Remdesivir NIH trial” to see the profit sharing scheme that may be disputed in court.
